Medigus Ltd. ($MDGS) announced that it has completed its first MUSE procedure in China.  the procedure was reported successful, with the patient encountering minimal discomfort during the procedure. The patient has since been released from the hospital, with no procedural complications. 
Chris Rowland, CEO of Medigus said, “With the completion of our first-in-man MUSE procedure in China we are looking forward to working with leading GIs across the country to implement this procedure and uniquely address the existing gap in GERD treatment between drug therapy and invasive laparoscopic procedures."
The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. It comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, enabling a single physician to perform an incisionless transoral fundoplication. It does not require any incisions, leading to shorter hospital stay and greater comfort for the patient.
Medigus stock shot up over 14 percent in its Wednesday trading session, touching its 52 weeks high of $70. The stock is up 32 percent this year so far while its 12 months loss is now down to 54 percent. The company had recently announced receiving its first purchase order for MUSE in Italy. Medigus is engaged  in the research and development of endoscopic procedures and devices.